NMTC NEUROONE MEDICAL TECHNOLOGIES Corp
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1500198 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY42.8%
TTM net income YoY-39.5%
TTM EPS YoY-20.9%
Revenue 3-yr CAGR94.9%
Net income 3-yr CAGR—
Margins
Gross margin55.6%
Operating margin-83.4%
Net margin-78.6%
FCF margin-75.6%
EBITDA margin-81.0%
Returns
ROE-124.7%
ROA-87.6%
ROIC (approx.)-671.9%
Asset turnover1.11x
Leverage & solvency
Liabilities / assets39.1%
Debt / equity0.00x
Current ratio2.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.95x
Accruals ratio-4.6%
Payout ratio—
Capex / revenue1.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-09-30 | FY20242024-09-30 |
|---|---|---|
| Income statement | ||
| Revenue | $9.10M | $3.45M |
| Cost of revenue | $3.96M | $2.37M |
| Gross profit | $5.14M | $1.08M |
| R&D expense | $4.98M | $5.07M |
| SG&A expense | $7.38M | $7.90M |
| Operating income | -$4.23M | -$11.89M |
| Pretax income | -$3.61M | -$12.32M |
| Net income | -$3.61M | -$12.32M |
| EBITDA | -$3.96M | -$11.64M |
| EPS (basic) | -0.09 | -0.46 |
| EPS (diluted) | -0.09 | -0.46 |
| Weighted avg. shares (diluted) | 40.15M | 26.76M |
| Balance sheet | ||
| Cash & equivalents | $6.57M | $1.46M |
| Receivables | $1.26M | $176,636 |
| Inventory | $2.23M | $2.64M |
| Current assets | $10.23M | $4.63M |
| PP&E, net | $259,222 | $416,843 |
| Intangibles | $44,946 | $67,262 |
| Total assets | $10.79M | $5.37M |
| Current liabilities | $2.30M | $2.21M |
| Total liabilities | $3.71M | $4.55M |
| Shareholders' equity | $7.07M | $822,013 |
| Shares outstanding | 8.33M | 30.82M |
| Cash flow statement | ||
| Operating cash flow | -$2.84M | -$11.01M |
| Capital expenditure | $81,742 | $120,197 |
| Free cash flow | -$2.92M | -$11.13M |
| Investing cash flow | -$81,742 | -$120,197 |
| Financing cash flow | $8.03M | $7.27M |
| Depreciation & amortization | $261,679 | $246,791 |
| Stock-based compensation | $1.26M | $1.34M |
Free plan shows the latest 2 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.